Show simple item record

dc.contributor.authorMorgan, Michael C.
dc.contributor.authorAtri, Lavannya
dc.contributor.authorHarrell, Sean
dc.contributor.authorAl-Jaroudi, Wael
dc.contributor.authorBerman, Adam Eric
dc.date.accessioned2023-10-11T16:21:16Z
dc.date.available2023-10-11T16:21:16Z
dc.date.issued2022-07-26
dc.identifier.citationMorgan, M. C., Atri, L., Harrell, S., Al-Jaroudi, W., & Berman, A. E. (2022). COVID-19 vaccine-associated myocarditis. World Journal of Cardiology, 14(7), 382-391. https://doi.org/10.4330/wjc.v14.i7.382en_US
dc.identifier.issn1949-8462
dc.identifier.urihttp://hdl.handle.net/10675.2/624822
dc.description.abstractMyocarditis is now recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccination, particularly in adolescent and young adult males. Since the authorization of the Pfizer-BioNTech™ and Moderna™ mRNA vaccines targeting the severe acute respiratory syndrome coronavirus-2 (SARSCoV- 2) spike protein, the Centers for Disease Control and Prevention (CDC) has reported 1175 confirmed cases of myocarditis after COVID-19 vaccination in individuals ages 30 years and younger as of January 2022. According to CDC data in June 2021, the incidence of vaccine-mediated myocarditis in males ages 12-29 years old was estimated to be 40.6 cases per million second doses of COVID-19 mRNA vaccination administered. Individuals with cases of COVID-19 vaccinemediated myocarditis typically present with acute chest pain and elevated serum troponin levels, often within one week of receiving the second dose of mRNA COVID-19 vaccination. Most cases follow a benign clinical course with prompt resolution of symptoms. Proposed mechanisms of COVID-19 vaccine myocarditis include molecular mimicry between SARS-CoV-2 spike protein and self-antigens and the triggering of preexisting dysregulated immune pathways in predisposed individuals. The higher incidence of COVID-19 vaccine myocarditis in young males may be explained by testosterone and its role in modulating the immune response in myocarditis. There is limited data on long-term outcomes in these cases given the recency of their occurrence. The CDC continues to recommend COVID-19 vaccination for everyone 5 years of age and older given the greater risk of serious complications related to natural COVID-19 infection including hospitalization, multisystem organ dysfunction, and death. Further study is needed to better understand the immunopathology and long-term outcomes behind COVID- 19 mRNA vaccine-mediated myocarditis.en_US
dc.language.isoen_USen_US
dc.publisherBaishideng Publishing Groupen_US
dc.relation.url10.4330/wjc.v14.i7.382en_US
dc.subjectCOVID-19en_US
dc.subjectMyocarditisen_US
dc.subjectPericarditisen_US
dc.subjectSARS-CoV-2en_US
dc.subjectmRNA vaccineen_US
dc.titleCOVID-19 vaccine-associated myocarditisen_US
dc.typeAbstracten_US
dc.typeArticleen_US
dc.typeJournal Volume/Issueen_US
dc.contributor.departmentAugusta Universityen_US
dc.identifier.journalWorld Journal of Cardiologyen_US
refterms.dateFOA2023-10-11T16:21:17Z


Files in this item

Thumbnail
Name:
WJC-14-382.pdf
Size:
2.822Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record